Aging
Navigate
Research Perspective|Volume 10, Issue 12|pp 3657—3661

Autophagy delays progression of the two most frequent human monogenetic lethal diseases: cystic fibrosis and Wilson disease

Luigi Maiuri1,2, Guido Kroemer3,8
  • 1Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
  • 2European Institute for Research in Cystic Fibrosis, San Raffaele Scientific Institute, Milan, Italy
  • 3Equipe11 Labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
  • 4INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
  • 5Université Paris Descartes, Paris, France
  • 6Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
  • 7Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
  • 8Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
Received: December 10, 2018Accepted: December 15, 2018Published: December 19, 2018

Copyright: © 2018 Maiuri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cystic fibrosis (CF) and Wilson disease (WD) are two monogenetic, recessively inherited lethal pathologies that are caused by ionic disequilibria. CF results from loss-of-function mutations in CF transmembrane conductance regulator (CFTR), a channel that conducts chloride across epithelial cell membranes, while WD is due to a deficiency of ATPase copper transporting beta (ATP7B), a plasma membrane protein that pumps out copper from cells. Recent evidence suggests that both diseases are linked to perturbations in autophagy. CFTR deficiency causes an inhibition of autophagic flux, thus locking respiratory epithelial cells in a pro-inflammatory state and subverting the bactericidal function of macrophages. WD is linked to an increase in autophagy, which, however, is insufficient to mitigate the cytotoxicity of copper. Pharmacological induction of autophagy may delay disease progression, as indicated by preclinical evidence (for CF and WD) and results from clinical trials, in particular in CF patients with the most frequent CTRT mutation (CFTRdel506). Thus, CF and WD exemplify pathologies in which insufficient autophagy plays a major role in determining the chronology of disease progression, much like the pace of ‘normal’ aging that is dictated by disabled autophagy as well.